Various actions of oestrogens on the vascular system

Maturitas

Volumn 30, Issue 1, 1998, Pages 5-9

  Stevenson, J C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atheroma; Cardiovascular disease; Hormone replacement therapy; Vascular endothelium

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; METALLOPROTEINASE; NORETHISTERONE; NORGESTREL;

ADULT; ATHEROMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; FEMALE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032552654     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00053-X     Document Type: Article

References (40)

1. Stampfer MJ, Grodstein F. Role of hormone replacement in cardiovascular disease. In: Lobo RA, editor. Treatment of the Postmenopausal Woman, Basic and Clinical Aspects. New York: Raven Press, 1994:223-33.
2. Spencer C.P., Cooper A.J., Stevenson J.C. Clinical trials in progress with hormone replacement therapy. Exp Opin Invest Drugs. 5:1996;739-779.
3. Bengtsson C., Björkelund C., Lapidus L., Lissner L. Associations of serum lipid concentrations and obesity with mortality in women, 20 year follow up of participants in prospective population study in Gothenburg Sweden. Br Med J. 307:1993;1385-1388.
4. Whitcroft S.I., Crook D., Marsh M.S., Ellerington M.C., Whitehead M.I., Stevenson J.C. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol. 84:1994;222-226.
5. van der Mooren M.J., de Graaf J., Demacker P.N., de Haan A.F., Rolland R. Changes in the low-density lipoprotein profile during 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women. Metabolism. 43:1994;799-802.
6. Campos H., Walsh B.W., Judge H., Sacks F.M. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab. 82:1997;3955-3963.
7. Sack M.N., Rader D.J., Cannon R.O. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 343:1994;269-270.
8. Koh K.K., Mincemoyer R., Bui M.N.et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. New Engl J Med. 336:1997;683-690.
9. Westerveld H.T., Kock L.A.W., van Rijn J.M., Erkelens D.W., de Bruin T.W.A. 17β-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab. 80:1995;249-253.
10. Crook D., Cust M.P., Gangar K.F.et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 166:1992;950-955.
11. Crook D., Godsland I.F., Hull J., Stevenson J.C. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol. 104:1997;298-304.
12. Stout R. Insulin and atheroma: 20-year perspective. Diabetes Care. 13:1990;631-654.
13. Notelovitz M., Johnston M., Smith S., Kitchens C. Metabolic and hormonal effects of 25 and 50 mg 17β estradiol implants in surgically menopausal women. Obstet Gynecol. 70:1987;749-754.
14. Cagnacci A., Soldani R., Carriero P., Paoletti A., Fioretti P., Melis G. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab. 74:1992;1396-1400.
15. Spellacy W.N., Buhi W.C., Birk S.A. The effects of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred and seventy one women ingesting Premarin, mestranol and ethinyl estradiol for 6 months. Am J Obstet Gynecol. 114:1972;378-392.
16. Godsland I.F., Gangar K.F., Walton C.et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 42:1993;846-853.
17. Winkler U.H. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis. 6(Suppl 3):1992;5-10.
18. Paganini-Hill A., Ross R.K., Henderson B.E. Postmenopausal oestrogen treatment and stroke: a prospective study. Br Med J. 297:1988;519-522.
19. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;392-395.
20. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogen. Lancet. 348:1996;981-983.
21. Grodstein F., Stampfer M.J., Goldhaber S.Z.et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
22. Perez-Gutthann S., Garcia-Rodriguez L.A., Castellsague J., Duque-Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J. 314:1997;796-800.
23. Scarabin P.-Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterioscler Thromb Vasc Biol. 17:1997;3071-3078.
24. Fox J., George A.J., Newton J.R.et al. Effect of transdermal oestradiol on thehaemostatic balance of menopausal women. Maturitas. 18:1993;55-64.
25. Magness R.R., Rosenfeld C.R. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. Am J Physiol. 256:1989;E536-542.
26. Gangar K.F., Vyas S., Whitehead M., Crook D., Meire H., Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet. 338:1991;839-842.
27. Hillard T.C., Bourne T.H., Whitehead M.I., Crayford T.B., Collins W.P., Campbell S. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril. 58:1992;959-963.
28. Rosano G.M.C., Sarrel P.M., Poole-Wilson P.A., Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 342:1993;133-136.
29. Collins P., Shay J., Jiang C., Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 90:1994;1964-1968.
30. Wingrove C.S., Stevenson J.C. 17β-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur J Endocrinol. 137:1997;205-208.
31. Williams J.K., Adams M.R., Klopfenstein H.S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation Res. 81:1990;1680-1687.
32. Gilligan D.M., Badar D.M., Panza J.A., Quyumi A.A., Cannon III R.O. Acute vascular effects of estrogen in postmenopausal women. Circulation. 90:1994;786-791.
33. Collins P., Rosano G.M.C., Sarrel P.M.et al. 17β-estradiol attentuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 92:1995;24-30.
34. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 106:1992;739-745.
35. White R.E., Darkow D.J., Falvo Lang J.L. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res. 77:1995;936-942.
36. Buikema H., Pinto Y.M., Rooks G., Grandjean J.G., Schunkert H., van Gilst W.H. The deletion polymorphism of the anfiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J. 17:1996;787-794.
37. Schuster H., Wienker T.F., Stremmler U., Noll B., Steinmetz A., Luft F.C. An angiotensin-converting enzyme gene variant is associated with acute myocardial infarction in women but not in men. Am J Cardiol. 76:1995;601-603.
38. Proudler A.J., Crook D., Godsland I.F., Collins P., Rosano G.M.C., Stevenson J.C. Serum angiotensin-I-converting enzyme activity in women with cardiological syndrome X: relation to blood pressure and lipid and carbohydrate metabolic risk markers for coronary heart disease. J Clin Endocrinol Metab. 80:1995;696-699.
39. Dollery C.M., McEwan J.R., Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res. 77:1995;863-868.
40. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17β-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998;1406:169-74.